← All trials
NCT01680003
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2012
- Primary completion
- Oct 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Nova Laboratories LimitedLead sponsor
- Sultanah Bahiyah Hospital, Alor StarOverall official - principal investigator
- Selayang Hospital, SelangorOverall official - principal investigator
- Tengku Ampuau Afzan Hospital, KuantanOverall official - principal investigator
- Queen Elizaberth Hospital, SabahOverall official - principal investigator
- Ampang Hospital, MalaysiaOverall official - principal investigator
- Kuala Lumpur General HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.